Anti-SKP2 antibody [EPR3306(2)] - BSA and Azide free

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

S-phase kinase-associated protein 2 (SKP2) also known as FBL1 or p45 is an E3 ubiquitin ligase that tags proteins for degradation. It weighs around 48 kDa. SKP2 facilitates the transition from the G1 to S phase of the cell cycle by targeting cyclin-dependent kinase inhibitors for proteasomal destruction. Expressed in various tissues including key roles in proliferating cells SKP2 ensures the regulation of cell cycle progression and stability.

Biological function summary

SKP2 is part of the SCF (SKP1-CUL1-F-box) complex which is instrumental in controlling cell cycle and cell division. It regulates the degradation of p27^Kip1 and other cell cycle regulators. By modulating proteolysis SKP2 contributes to the maintenance of cell proliferation and it has essential roles in cellular responses to growth signals. Moreover SKP2 influences processes such as DNA replication through its effect on substrate interaction and ubiquitination.

Pathways

SKP2 functions inside the ubiquitin-proteasome system and impacts the PI3K/AKT signaling pathway. SKP2 advances cell cycle progression by associating with proteins like p27^Kip1 and CDK2 facilitating cell division. It modulates the phosphorylation state of numerous targets influencing signaling processes that control cell growth. This involvement aligns SKP2 with key cellular pathways that maintain cell survival and metabolic balance.

Associated diseases and disorders

SKP2 plays an important role in cancer and cardiovascular diseases. In various cancers the aberrant expression of SKP2 connects to excessive cell proliferation and tumor growth partially through interactions with oncoproteins like Myc. In cardiovascular conditions SKP2 influences cardiac hypertrophy and might link to proteins such as cyclin-dependent kinase inhibitors. The regulation by SKP2 affects these proteins' stability impacting disease progression and potential therapeutic interventions.